Successful immunotherapy with matrix metalloproteinase-derived peptides in adjuvant arthritis depends on the timing of peptide administration

Arthritis Res. 2002;4(4):R2. doi: 10.1186/ar421. Epub 2002 May 7.

Abstract

We have recently found that matrix metalloproteinases (MMPs) are targets for T-cell and B-cell reactivity in experimental arthritis. In the present article, we investigate whether modulation of MMP-specific T-cell responses could influence the course of adjuvant arthritis (AA). Lewis rats were treated nasally with MMP peptides prior to or after AA induction. Administration of the MMP-10 or the MMP-16 peptide prior to AA induction reduced the arthritic symptoms. In contrast, administration of the MMP-10 peptide after AA induction aggravated the arthritic symptoms. The present study shows the possible usefulness of MMP peptides for immunotherapy. However, a clear understanding of proper timing of peptide administration is crucial for the development of such therapies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intranasal
  • Animals
  • Arthritis, Experimental / immunology*
  • Arthritis, Experimental / physiopathology
  • Arthritis, Experimental / therapy*
  • Immunotherapy / methods*
  • Male
  • Matrix Metalloproteinase 3 / administration & dosage
  • Matrix Metalloproteinase 3 / immunology
  • Matrix Metalloproteinases / administration & dosage
  • Matrix Metalloproteinases / immunology*
  • Peptides / administration & dosage
  • Peptides / immunology
  • Rats
  • Rats, Inbred Lew
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology
  • Time Factors
  • Treatment Outcome

Substances

  • Peptides
  • Matrix Metalloproteinases
  • Matrix Metalloproteinase 3